C-peptide
Also known as: C peptide, Connecting peptide, Insulin C-peptide, Insulin C‑peptide, Proinsulin C-peptide, Proinsulin C‑peptide
Source C-peptide at Peptiology
Save 10% with code PEPTI-BOSSRABBIT-10
Affiliate link: we earn a commission on purchases made through this link, at no extra cost to you.
Tapping Shop Now & Save 10% copies your 10% off code PEPTI-BOSSRABBIT-10 to your clipboard. Paste it at the Peptiology checkout to claim the discount.
Summary
C‑peptide is a 31‑amino‑acid fragment cleaved from proinsulin during insulin biosynthesis. Although it has no insulin‑like glucose‑lowering activity, it circulates in proportion to endogenous insulin secretion and is used as a biomarker of residual beta‑cell function. In research settings it is administered intravenously or subcutaneously to explore potential renoprotective actions in early diabetic kidney disease.
Mechanism of Action
Beyond its role as a by‑product of insulin synthesis, C‑peptide exhibits intrinsic biological activity. Experimental studies suggest it can modulate renal hemodynamics, reducing glomerular hyperfiltration and proteinuria, possibly through endothelial nitric‑oxide pathways and Na⁺/K⁺‑ATPase regulation, although the exact receptors and downstream signalling remain incompletely defined.
What the Research Shows
C‑peptide is most frequently measured as an outcome in trials aiming to preserve beta‑cell function; a 2025 network meta‑analysis of 41 immunomodulatory interventions reported higher C‑peptide levels with several therapies in newly diagnosed type 1 diabetes. As a therapeutic agent, a 2015 systematic review identified four small human trials (74 participants) and numerous animal studies. Human data showed no overall change in glomerular filtration rate but reported reductions in hyperfiltration and albuminuria; animal models consistently demonstrated lowered GFR, proteinuria, and mesangial expansion. Overall, evidence for a direct clinical benefit of C‑peptide therapy is limited and derived mainly from short‑term, low‑powered studies.
Reported Benefits
C‑peptide serves as a reliable surrogate of endogenous insulin secretion, aiding assessment of disease progression and response to immunotherapies in type 1 diabetes. Preliminary therapeutic data suggest it may attenuate early diabetic nephropathy by reducing hyperfiltration and albumin excretion, findings supported by multiple rodent experiments and modest human signals.
Limitations of the Evidence
Human trials of C‑peptide therapy are few, short‑duration, and under‑powered, limiting confidence in efficacy conclusions. The systematic review noted heterogeneity among animal models and a lack of long‑term outcome data. Moreover, C‑peptide has not been evaluated in large, placebo‑controlled phase III studies, and its mechanistic pathways remain incompletely mapped.
Safety Considerations
No major adverse events were reported in the small human studies or in animal experiments, and short‑term administration appeared well tolerated. However, the limited sample size and brief follow‑up mean rare or delayed toxicities cannot be excluded. Ongoing monitoring in future trials is warranted.
How It Is Administered
In research protocols C‑peptide is delivered as a synthetic peptide via intravenous infusion or subcutaneous injection. Formulations are typically sterile aqueous solutions; dosing regimens vary across studies and are not standardised for clinical use.
Routes of Administration
Goals & Uses
- Cardiac function improvement in type 1 diabetesCardioprotectionLow
- Diabetic peripheral neuropathy improvementNeuroprotection / Nerve FunctionModerate
- Microvascular blood flow improvementVascular FunctionModerate
- Renal protection in diabetesNephropathyLow
- Diabetic neuropathy treatmentNeuropathyModerate
- Endogenous insulin secretion biomarkerDiagnostic / MonitoringHigh
- Diabetic nephropathy attenuationRenal ProtectionModerate
Contraindications
- Known hypersensitivity to C‑peptideAllergyHigh
- Hypersensitivity to C-peptide or formulation componentsImmunologicHigh
- Type 2 diabetes or conditions with endogenous C-peptideEndocrineModerate
Adverse Effects
- HypoglycemiaMetabolicRareAbnormally low blood glucose
- Injection site reactionsLocalCommon
- Antibody FormationImmunologicalUnknown
- NauseaGastrointestinalUncommonFeeling of sickness or urge to vomit
- Injection site reactionLocalCommonRedness, swelling, itching, bruising, or pain at the injection site
Drug Interactions
- InsulinLowMay increase risk of low blood sugar
- ACE inhibitors / ARBsLow
Population Constraints
- PregnancyReproductive SafetyRelative
- Renal impairmentOrgan ImpairmentRelative
- Pediatric patientsAgeRelative
- Pregnant womenReproductiveRelative
Regulatory Status
- European UnionInvestigationalClinical trials ongoing.
- United StatesInvestigationalUnder IND for diabetic neuropathy.
- United KingdomInvestigationalNo MHRA approval for therapeutic use. Diagnostic use established via laboratory assay.
Not approved as a therapeutic agent; studied in phase II/III trials for neuropathy.
Evidence & Sources
- Journal ArticleHighBeese SE, et al.2025-01-01T00:00:00.000000Z
- Journal ArticleHighHabiba UE, et al.2024-01-01T00:00:00.000000Z
- Journal ArticleModerateHerold KC, et al.2013-01-01T00:00:00.000000Z
- Journal ArticleHighRebelos E, et al.2025-01-01T00:00:00.000000Z
- Journal ArticleHighSimental-Mendía LE, et al.2025-01-01T00:00:00.000000Z
- Journal ArticleHighShaw JA, et al.2015-01-01T00:00:00.000000Z
Frequently Asked Questions
Why is C‑peptide measured in diabetes research?
Because its concentration reflects endogenous insulin secretion, C‑peptide provides a direct estimate of residual beta‑cell function, which is essential for evaluating disease progression and the impact of immunomodulatory therapies in type 1 diabetes.
Can C‑peptide replace insulin therapy?
No. C‑peptide does not lower blood glucose and has not been shown to substitute for insulin. Its role is investigational, focusing on potential protective effects on kidney function rather than glycaemic control.
What evidence supports C‑peptide’s renoprotective effects?
Animal studies consistently show reductions in glomerular hyperfiltration, proteinuria, and mesangial matrix expansion after C‑peptide administration. Small human trials report modest decreases in albuminuria, but the data are insufficient to confirm a definitive clinical benefit.
Is C‑peptide approved for any therapeutic use?
No. C‑peptide remains an investigational peptide used only in research settings; it has not received regulatory approval for treatment of diabetes or kidney disease.
What are the main safety concerns with C‑peptide?
Current studies report no serious adverse events, but the limited size and duration of human trials mean rare or long‑term safety issues have not been fully evaluated. Ongoing vigilance in future trials is necessary.
What is C-peptide?
C‑peptide is a 31‑amino‑acid fragment cleaved from proinsulin during insulin biosynthesis. Although it has no insulin‑like glucose‑lowering activity, it circulates in proportion to endogenous insulin secretion and is used as a biomarker of residual beta‑cell function. In research settings it is administered intravenously or subcutaneously to explore potential renoprotective actions in early diabetic kidney disease.
What is C-peptide used for?
C-peptide is educationally associated with: Cardiac function improvement in type 1 diabetes, Diabetic peripheral neuropathy improvement, Microvascular blood flow improvement, Renal protection in diabetes, Diabetic neuropathy treatment, Endogenous insulin secretion biomarker, Diabetic nephropathy attenuation. Educational only — not medical advice.
How is C-peptide administered?
Recorded routes of administration: Intravenous, Subcutaneous.
What are the potential side effects of C-peptide?
Reported adverse effects include: Hypoglycemia, Injection site reactions, Antibody Formation, Nausea, Injection site reaction. This list is not exhaustive — consult a qualified clinician.
Who should avoid C-peptide?
Recorded contraindications: Known hypersensitivity to C‑peptide, Hypersensitivity to C-peptide or formulation components, Type 2 diabetes or conditions with endogenous C-peptide. Consult a qualified clinician before use.